On Tuesday December 8th, after his Nobel Lecture, Nordic Life Science met the Nobel Laureate in Chemistry, Professor Tomas Lindahl, for an interview at the Grand Hotel.
Professor Lindahl shared his thoughts about basic research, what fascinates him about science and chemistry and his hopes for the medical applications of his and the other Laureates findings.
Read the exclusive interview in our next issue of Nordic Life Science, out in the end of January.
Photo: Jenny Öhman
Onxeo has turned to the public markets for cash to fuel its research and development ambitions, starting a rights issue in a bid to raise up to €41.6 million ($52.2 million). The Franco-Danish biotech plans to use the cash to expand a Phase III study of its liver cancer drug…
AstraZeneca and Evotec have launched a research collaboration focused on developing new drugs for kidney disease, the second partnership involving entities of the pharma giant and the German drug discovery alliance and development partnership company. The value of the collaboration was not disclosed. Evotec will license a series of molecules…
Johnson & Johnson’s Janssen Pharmaceutical Companies plan to invest $10 million in a new UK government-led global dementia discovery fund for research to find ways to prevent and treat dementia and Alzheimer’s disease. The investment will come through its affiliate venture arm, Johnson & Johnson Innovation – JJDC, Inc. The…
Medicon Village, a Swedish cluster for life sciences, visited Wales’ new center for life sciences this month. The visit builds on a relationship which began 18 months ago when Life Sciences Hub Wales was chosen as Medicon Village’s first “twin.” The two organizations identified a number of areas where they…
